)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Stereotaxis
Stereotaxis (STXS) investor relations material
Stereotaxis Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Q3 priorities: scale accessible capital systems through GenesisX and Synchrony, and grow recurring revenue from disposable robotic catheters.
New system sales lifted revenue, while catheter supply limits and the transition away from Johnson & Johnson constrained recurring revenue.
Management sees a path to profitability in 2027, supported by recurring revenue growth and more consistent capital sales.
Financial highlights
Q3 revenue was $8.9M, up 20% YoY and 16% sequentially; 9M revenue was $22.9M versus $23.7M in 2025.
Q3 system revenue was $3.0M versus $1.9M YoY; recurring revenue was $5.9M, up 6% YoY and down 4% sequentially.
Operating and net losses were each $6.5M; 9M operating loss was $17.0M and net loss was $16.8M.
Adjusted Q3 operating and net losses were $5.1M and $5.2M, versus $2.5M and $2.4M YoY.
Operating expenses were $10.4M, including $1.3M of non-cash charges; adjusted operating expenses were $9.1M versus $6.6M YoY.
Outlook and guidance
Management expects recurring revenue growth and more consistent capital sales in coming quarters, with a pathway to profitability in 2027.
Adjusted operating expenses, excluding non-cash and one-time items, are expected to be ~$8M per quarter; revenue growth with stable expenses is expected to support cash-flow profitability within a year.
Gross margins are expected to remain near current levels in the near term, with significant expansion opportunity in 2027 and 2028.
A Q4 recurring revenue high watermark is expected, even without improved MAGiC shipments, primarily from alternative catheters in Europe.
Catheter supply constraints could be resolved in early 2027 following regulatory decisions supporting redundant supply.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Stereotaxis
- Robotic innovation, clinical validation, and global expansion drive strong growth and market leadership.STXS
Investor presentation - Recurring revenue surged 270% on new catheter adoption, with profitability targeted for early 2027.STXSQ2 2026
- Resale registration for 108M+ shares highlights dilution and integration risks after Robocath deal.STXSRegistration filing
- Registers 19.9% of shares for resale post-Robocath acquisition; no proceeds to company.STXSRegistration filing
- Robotic magnetic navigation and digital innovation drive safer, scalable endovascular surgery worldwide.STXSInvestor presentation
- Regulatory wins, new products, and Robocath deal drive optimism for double-digit 2026 growth.STXSQ1 2026
- Acquisition accelerates robotic leadership in endovascular care, targeting rapid market growth.STXSM&A announcement
- Vote on director elections, auditor ratification, and executive compensation by May 13, 2026.STXSProxy filing
- Q1 2025 revenue up 9% to $7.5M, driven by recurring revenue and innovation, despite higher net loss.STXSQ1 2025
Next Stereotaxis earnings date
Q4 20268 Mar, 2027
Stereotaxis
Next Stereotaxis earnings date
Q4 20268 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Stereotaxis designs, manufactures, and distributes robotic systems, instruments and information systems for the interventional laboratory in the United States, Canada and Europe. Stereotaxis products are sold to hospitals with interventional laboratories by a direct sales force. The company's remote magnetic navigation system provides a physician with computer-controlled robotic control of catheter positioning and ablation systems during minimally invasive procedures.
This year the company has introduced it's web based system for real-time data-analysis allowing doctors to predict arrhythmias up to 4 days before they happen. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.